Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) EBITDA (2016 - 2017)

Tenax Therapeutics' EBITDA history spans 8 years, with the latest figure at $1.4 million for Q4 2017.

  • For Q4 2017, EBITDA fell 95.97% year-over-year to $1.4 million; the TTM value through Dec 2017 reached $8.8 million, down 81.47%, while the annual FY2025 figure was -$56.4 million, 189.24% down from the prior year.
  • EBITDA for Q4 2017 was $1.4 million at Tenax Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $33.6 million in Q4 2016 and bottomed at -$1.6 million in Q1 2013.
  • The 5-year median for EBITDA is $3.4 million (2014), against an average of $5.3 million.
  • The largest annual shift saw EBITDA plummeted 184.94% in 2013 before it skyrocketed 310.55% in 2014.
  • A 5-year view of EBITDA shows it stood at $1.4 million in 2013, then skyrocketed by 180.58% to $4.0 million in 2014, then decreased by 23.1% to $3.1 million in 2015, then soared by 983.39% to $33.6 million in 2016, then plummeted by 95.97% to $1.4 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's EBITDA are $1.4 million (Q4 2017), $1.2 million (Q3 2017), and $3.0 million (Q2 2017).